Anti–PD-1 therapy (pembrolizumab, nivolumab) supports neoadjuvant and adjuvant management of higher-risk melanoma, offering durable remissions with less systemic toxicity than traditional chemotherapy ...

Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or non­melanoma skin cancer, which is also known as keratinocyte ...

Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing recurrence risk by 68% in the C-POST trial. Administered post-surgery and radiation ...

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas ASCO Guidelines ...

Medically reviewed by Susan Russell, MD Key Takeaways Squamous cell carcinoma begins in the tissues lining the air passages in the lungs.Common symptoms include a persistent cough, shortness of breath ...

Recent findings suggest no significant overall survival difference for patients with locally advanced esophageal squamous cell carcinoma who had neoadjuvant vs adjuvant therapy.

Impact of time to surgery on outcomes in patients with advanced esophageal squamous cell carcinoma following neoadjuvant therapy: An exploratory analysis of phase III trial JCOG1109. This is an ASCO ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Samuel J. Klempner ...